Central nervous system (CNS) injuries, such as stroke, traumatic brain injury (TBI) and spinal cord injury (SCI), are important causes of death and long-term disability worldwide. MicroRNA (miRNA), small non-coding RNA molecules that negatively regulate gene expression, can serve as diagnostic biomarkers and are emerging as novel therapeutic targets for CNS injuries. MiRNA-based therapeutics include miRNA mimics and inhibitors (antagomiRs) to respectively decrease and increase the expression of target genes. In this review, we summarize current miRNA-based therapeutic applications in stroke, TBI and SCI. Administration methods, time windows and dosage for effective delivery of miRNAbased drugs into CNS are discussed. The underlying mechanisms of miRNA-based therapeutics are reviewed including oxidative stress, inflammation, apoptosis, blood-brain barrier protection, angiogenesis and neurogenesis. Pharmacological agents that protect against CNS injuries by targeting specific miRNAs are presented along with the challenges and therapeutic potential of miRNA-based therapies.
MiRNAs in central nervous system injuries

Overview of miRNAs
MicroRNAs (miRNAs or miRs) are small RNA that do not code for proteins. 1, 2 The miRNA biogenesis and function have previously been reviewed in detail. 3 In brief, a miRNA gene is transcribed by RNA polymerase II (Pol II), generating the primary miRNA (primiRNA). In the nucleus, the RNase III endonuclease Drosha and the double-stranded RNA-binding domain (dsRBD) protein DGCR8/Pasha cleave the pri-miRNA to produce a 2-nt 3 0 overhang containing the 70-nt precursor miRNA (pre-miRNA). Exportin-5 transports the pre-miRNA into the cytoplasm. In the cytoplasm, the pre-miRNA is cleaved by another RNase III endonuclease, Dicer, together with the dsRBD protein TRBP/Loquacious, releasing the 2-nt 3 0 overhang containing a 21-nt miRNA:miRNA duplex. Each miRNA stand is incorporated into an Argonautecontaining RNA-induced silencing complex (RISC). The RISC-loaded miRNA contains seed region that binds to the complementary sequences in the 3 0 untranslated regions (3 0 UTRs) of its target genes (mRNAs), resulting in negative regulation, such as transcript degradation or post-translational suppression. Generally, each miRNA can regulate hundreds of target genes, 4 with greater than one-third of all human genes being predicted to be regulated by miRNAs. 5 MiRNAs are implicated in all cellular processes, including cell proliferation, cell differentiation and death, cellular metabolism, and immune responses in physiological as well as pathological conditions. [6] [7] [8] [9] Since their discovery in the 1990s, 1,2 they are being investigated as biomarkers for a variety of diseases including cancer, stroke, traumatic brain injury (TBI) and spinal cord injury (SCI). MiRNAs have also generated interest as drug targets, 35 because they have several desirable features for drug development including: (1) a single miRNA downregulates hundreds of targets by binding to the 3 0 UTR of its target genes; [36] [37] [38] [39] [40] [41] [42] (2) miRNAs are short 22 nucleotides in length for which miRNA drugs can easily be designed; (3) miRNAs are often conserved between species; 43 (4) miRNA drugs can be delivered in vivo via several drug delivery systems that have been approved for human use. 44, 45 Several pharmaceutical companies have been pursuing miRNA therapeutics over the last decade, with several miRNA drugs advanced to human trials, such as miravirsen, RG-101, RG-125/AZD4076, MRX34, and TagomiRs. 35, [45] [46] [47] [48] These studies support the feasibility of miRNA therapies for humans. Although most miRNA drugs in current clinical trials are focused on cancer, increasing numbers of miRNAbased drugs (e.g. anti-miR-497, anti-Let-7f, anti-miR-181, anti-miR-15a/16-1, anti-miR-23a, miR-424 mimic, miR-124 mimic, miR-122 mimic, miR-21 mimic, and others) have been tested in experimental stroke, TBI and SCI models. [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] We will discuss these miRNAbased therapeutic applications and the underlying mechanisms for non-CNS diseases and CNS injuries in detail in the following sections.
Altered miRNA profiles in CNS injuries
MiRNAs expression studies have demonstrated many miRNAs increase or decrease in brain, blood, CSF, and/or saliva after CNS injuries. [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] [31] [32] [33] [34] Targeting several miRNAs (e.g., miR-497, Let-7f, miR-181, miR-15a/16-1, miR-23a, miR-424, miR-124, miR-122, miR-21, others) that are altered after CNS injuries, we and others have examined the therapeutic efficacy of miRNA drugs (miRNA inhibitor or miRNA mimic in relation to one miRNA and one type of CNS injuries) to improve outcomes after experimental stroke, TBI or SCI. [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] [61] [62] [63] [64] Moreover, these miRNA studies are also beginning to broaden our understanding of the pathogenesis of these injuries.
As shown in Figure 1 , increases of miRNAs (miR-497, Let-7f, miR-181, miR-15a/16, miR-23a, miR-424) downregulate their target genes (i.e. Bcl-2, IGF-1, SHPA5, FGF2, FGFR1, VEGFR2), [49] [50] [51] [52] [53] [54] [55] [56] [57] [58] [59] [60] whereas decreases of miRNAs (miR-124, miR-122, miR-21) up-regulate their target genes (i.e. Src, ROCK, Pla2g2a, Rhdbf1, Nos2, PTEN). [61] [62] [63] [64] These complex miRNA-target interactions can affect many processes including neuronal death, neurogenesis, angiogenesis, platelet aggregation, leukocyte infiltration, blood-brain barrier (BBB) disruption, and tissue infarction that affect neurological deficits after CNS injuries ( Figure 1 ).
Circulating miRNAs as diagnostic and prognostic biomarkers for CNS injuries
MiRNA sequencing in cancer tissue has demonstrated the potential of miRNAs for diagnostics in clinical applications. [10] [11] [12] [13] Because sampling brain tissue from living humans is not practical for most neurological diseases, investigators have used blood, plasma, CSF, and saliva as accessible sources of RNA to perform miRNA expression profiling studies in CNS diseases. 66 MiRNAs in various biofluids are very stable, often found in association with Argonaut protein, microvesicles, or exosomes which protect them from RNAases, and represent potentially informative biomarkers for a range of diseases including CNS injuries. 12, 67 Blood is often used when studying immune response and blood coagulation in CNS injuries. 68 This is because a large number of blood cells (leukocytes, platelets, erythrocytes) contain abundant miRNAs and play critical roles in CNS injuries, including inflammatory response, platelet aggregation, platelet-monocyte complexes, leukocytes adhesion to endothelium and subsequent leukocytes infiltration that result in BBB disruption and parenchymal CNS injuries ( Figure 2 ). [69] [70] [71] [72] [73] [74] [75] [76] [77] Recent interest has focused on the potential diagnostic and prognostic application of plasma, serum and saliva miRNAs. It has been suggested that the changes of miRNAs in plasma or saliva may be derived from injured CNS cells and recruited blood cells, as microvesicles and exosomes containing miRNAs are released from these cells into plasma and saliva. 78, 79 However, the origin and release mechanisms of miRNAs found in plasma and saliva are still not thoroughly understood.
MiRNAs as biomarkers in animal models. Jeyaseelan et al. 18 first examined miRNA expression profiles in whole blood after transient ischemic stroke. They found: (1) miR-19b, miR-290, and miR-292-5p increased and miR-103 and miR-107 decreased after 24-h reperfusion; and (2) miR-150, miR-195, miR-352, miR-26b, miR-103, miR-107, miR-26a, let-7c and others changed expression after 48-h reperfusion. 18 Using Taqman rodent miRNA arrays, we examined miRNA expression profiles in whole blood and brain 24 h after ischemic stroke, hemorrhagic stroke, and kainic acid induced status epilepticus. 19 These data showed: (1) the blood miRNA response profiles were different for each condition; (2) many miRNAs changed more than 1.5 fold in blood and brain after each experimental manipulation, and several miRNAs were up-or down-regulated in both brain and blood after a given injury; (3) a few miRNAs (e.g. miR-298, miR-155, miR-362-3p) were up-or down-regulated more than 2-fold in both brain and blood after several different injuries. 19 These two studies confirmed that blood miRNAs could be of utility as biomarkers for CNS injuries. 18, 19 Subsequent studies have shown miR-124 increases 150-fold in plasma after ischemic stroke. 20 Let-7i, miR-122, miR-340-5p, miR-200b, and miR-874 are modulated in serum after post-blast TBI in rats. 21 MiR-9, miR-219 and MiR-384-5p increased in the serum of mice 12 h after SCI. 33 MiR-133a-5p, miR-378, miR-378b-3p, miR-365-3p, miR-133b, miR-10b, miR-885-5p, miR-130a, miR-100, miR-208b and others were altered in serum at 1 and 3 days after SCI in pigs, and these strongly correlated with outcome measures at 12 weeks post SCI. 34 MiRNAs as biomarkers in patients. In patients with stroke and TBI, differences in miRNA levels have been reported for extracellular miRNA in plasma (circulating miRNA), and for intracellular miRNA from blood cells. 80 In the subacute and chronic phase of ischemic stroke, circulating plasma levels of miR-21, miR-221, 81 and miR-145 82 are increased, whereas miR-210 is decreased. 83 In acute stroke, circulating miR-143-3p, miR125a-5p, miR-125b-5p are reported to be increased in both derivation and validation cohorts. 84 A decrease in miR-150-5p measured within 72 h is a predictor of 90-day mortality. 85 A number of other extracellular miRNAs have been associated with stroke as reviewed by Dewdney et al. 86 In TBI, a number of circulating miRNAs are reported to change, with an increase in miR-765, miR-16, miR-125-5b, miR-1515, miR-199a-3p, miR-20a, miR-21, miR-27a, miR-27b, miR-30d, miR-328, miR-335, Figure 2 . Function of circulating microRNAs in CNS injuries. During CNS injuries, decreased miRNAs in blood lead to upregulation of their target inflammatory genes and blood clotting genes, and thus results in multiple outcomes after CNS injuries, including leukocyte-platelet-endothelium complexes, platelet aggregation, leukocyte infiltration, BBB disruption, tissue infarction, neurological deficits, and others. MiRNA mimics replace the decreased miRNAs in blood and accordingly attenuate these detrimental outcomes after CNS injuries.
miR-362-3p, miR-92a, miR-486, miR-505*, miR-451 and decreases in miR-142-3p, miR-423-3p, miR-425-5p, and miR-502. [23] [24] [25] 87 Several miRNAs changed in stroke overlap with those in TBI including miR-125-5b, miR-16 and miR-27a.
There has been substantial variability in the extracellular miRNA reported to be different between these studies. Most have been small and had differences in time of sample collection post-stroke, patient characteristics, methods of sample collection, methods of RNA isolation and miRNA measurement, and methods to assess for cell lysis contribution to extracellular miRNA. Factors such as type of tube used for blood collection, volume of blood collected, time from collection to processing, centrifugation speed and time and freeze thaw cycles all are reported to affect microparticle generation and circulating miRNA. 88 As our understanding of circulating miRNA improves, it is clear that standardized protocols for circulating miRNA are needed for future studies in stroke. The source of miRNA in plasma also remains to be established. The differential contribution of platelets and peripheral blood cells as well as other tissues to the circulating miRNA pool may account for some of the variability observed in studies. 88 Levels of miRNA in plasma are very low, thus small contributions from other tissues or lysed cells could significantly impact results.
At the intracellular level, miRNAs in circulating leukocytes and other blood cells in patients with stroke have been studied. In a study of chronic stroke 6-18 months post event, 157 miRNAs were differentially expressed in young stroke compared to healthy controls. 89 In acute stroke, we reported miR-122, miR148a, let-7i, miR-19a, miR-320d, miR-4429 were decreased and miR-363, miR-487b were increased compared to vascular risk factor controls. 22, 90 Several of the identified miRNAs in acute cerebral ischemia overlap with those reported in subacute and chronic stroke including miR-19a, miR-320d, miR-363, and miR487b. In patients with stroke, let-7i microRNA has been shown to regulate important aspects of the immune response in cerebral ischemia. 90 Further study is needed to determine the course of miRNA changes over time after ischemic stroke as well as how intracellular miRNA relates to extracellular plasma cellular miRNA.
Development and therapeutics of miRNA-based drugs for non-CNS diseases
MiRNA-based therapeutics can presently be divided into two categories: miRNA mimics and miRNA inhibitors. If specific miRNAs are downregulated and correlate with disease progression, miRNA mimics could compensate for the functional activity of the lost miRNAs. In contrast, if specific miRNAs are upregulated and appear to contribute to disease pathogenesis, it might be beneficial to suppress the over-expressed miRNAs using miRNA inhibitors (or antimiRs).
Overview of miRNA mimics and inhibitors
MiRNA mimics are synthetic short double-stranded oligonucleotides imitating miRNA precursors. Once introduced into cells, these oligonucleotides can be recognized by miRNA biogenesis machinery and processed accordingly. 91, 92 Since the strand of interest (guide strand) needs to be identical to the native mature miRNA, miRNA mimics are constructed with one ''guide strand'' and one fully or partially complementary ''passenger strand. '' 91 MiRNA inhibitors inhibit the interaction between miRNA and the microRNA-induced silencing complex (miRISC) proteins or between the miRISC and its target mRNAs. 93 AntimiRs were originally designed as single-stranded antisense oligonucleotides (ASOs), which traditionally target a specific mRNA to block its translation into protein or trigger its destruction. 94 AntimiRs now refer to the modified ASOs having the full or partial complementary reverse sequence of a mature miRNA. 45, 95 Chemical modifications of miRNA mimics and inhibitors For miRNA mimics, the ''guide strand'' must be identical to mature miRNA, and position-specific chemical modifications are made to the ''passenger strand'' to ensure that only the ''guide strand'' is loaded onto the RISC. 96 To enhance the stability but not interfere with the recognition by the RISC, only limited chemical modifications can be made to the ''guide strand.'' 97 The 2 0 -sugar modification, such as 2 0 -O-methyl and 2 0 -fluoro (2 0 -F), helps to protect against nucleases, which improve the potency and stability of the guide strand without interfering with RISC loading. 98, 99 Strategies to improve the cellular uptake, such as cholesterol conjugation, can also result in off-target effects. 95 Currently, commercially available miRNA mimics are normally modified by methylation of the ''passenger strand'' for increased stability, 45 though vendors often do not disclose their chemical modifications. 100 Several chemical modifications have improved the stability, permeability and specificity of miRNA inhibitors. 95, 101 Current modifications include phosphorothioate containing oligonucleotides, 102,103 addition of
0 -O-methoxyethyl-Oligonucleotides (2 0 -O-MOE, which are also called antagomirs), 104 locked nucleic acid (LNA) modified antimiRs, 105 fluorine derivatives (2 0 deoxy-2 0 -fluoro-RNA), 106 peptide nucleic acids modified antimiRs 107, 108 or mixed modifications among these approaches. As a traditional and non-specific modification, cholesterol conjugation at the 3 0 end of the strand can improve tissue distribution and cellular uptake. 109 Novel chemical modifications are continuing to be developed like a pH low insertion peptide-modified antimiR to inhibit miR-155 in lymphoma. 110 
MiRNA-based therapeutics for non-CNS diseases in animal models
There has been an enormous increase in studies of the role of miRNA in human diseases using a variety of animal disease models. 32, 45, [111] [112] [113] [114] [115] [116] [117] [118] [119] MiRNA-based therapeutic studies in animals ( Figure 3 (a)) have provided new avenues for drug development for different human diseases. 32, 45, [111] [112] [113] [114] [115] [116] [117] [118] [119] Though this review focuses on CNS injuries, miR treatments are being tested in variety of pathological conditions in animal models.
Examples include heart failure, 120 where miR-17-92, miR-126, miR-24, miR-214 and miR-34 show antiangiogenic effects, while miR-210 exhibits proangiogenic functions. 112, 121 Cardiac hypertrophy, which can precede heart failure, 122 can be abrogated with miR-1 mimic, 123 Cardiomyocyte death, which can accompany heart failure, 127 can be decreased by carvedilol, a b-adrenergic blocker, which increases miR-133 expression. 128 Intravenous (IV), chemically modified, cholesterolconjugated miR-122 antagomir reduced miR-122 levels in liver and decreased hepatitis C virus (HCV) replication.
111,129 IV LNA-modified miR-122 antagomir in chimpanzees chronically suppressed HCV viremia. 130 In hepatocellular carcinoma, miR-122 silencing in liver reduced tumor cell proliferation, increased apoptosis and cell-cycle arrest, and increased mouse survival. 131 A miR-24 antagomir in an obesity mouse model alleviated hyperlipidemia and fatty liver. 132 An LNAantimiR to miR-122 in African green monkeys increased hepatic fatty acid oxidation and reduced plasma cholesterol and cholesterol synthesis. 133 Antagomirs of miR-33a and miR-33b in African green monkeys increased plasma HDL-cholesterol. LNA-miR-146b antagomir significantly reduced body weight and fat volume in mice fed a high-fat diet. 135 MiR-103/107 antagomir improved glucose homeostasis and insulin sensitivity, suggesting a treatment for type 2 diabetes and obesity. 136 In cancer research, IV miR-34 mimic reduced tumor growth and enhanced survival rates in mouse models of hepatocellular carcinoma (HCC). 137 MiR-34 mimics also improve outcomes in animal cancer models of liver, 138 prostate, 139 lung, 138 and pancreas. 140 MiR-200 family members improve outcomes for ovarian and lung cancers, 141, 142 miR-26a for hepatocellular cancer, 143 miR-506 and miR-520 for ovarian cancer, 144, 145 and miR-15/16 cluster for leukemia. 146 Anti-miR-10b improved breast cancer outcomes, 147 anti-miR-221 treatment improved HCC, 131 anti-miR-155 treatment improved lymphoma 110, 148 and antimiR-630 improved ovarian cancer. 149 
MiRNA-based therapeutics for non-CNS diseases in patients
Several miRNA-based drugs tested in preclinical animal models have been advanced to human clinical trials including miravirsen, RG-101, RG-125/ AZD4076, MRX34, and TagomiRs (Figure 3(b) ). Although none of these miRNA-based drugs in human clinical trials are related to the brain, these drugs still indicate their great potential in the therapeutic application for CNS injuries.
Miravirsen, a miR-122 inhibitor, entered phase IIa clinical trials. 46 Subcutaneous injections of miravirsen in patients with chronic HCV genotype 1 infection showed prolonged dose-dependent reductions in HCV RNA levels without evidence of viral resistance or side effects. 46 RG-101, another miR-122 inhibitor, has completed a phase I trial targeting HCV-infected patients as well. 45 A single subcutaneous dose of RG-101 produced a sustained viral load reduction with a favorable safety profile.
RG-125/AZD4076, an N-acetylgalactosamine (GalNAc)-conjugated anti-miR-103/107 oligonucleotide, was proceeded to a phase 1/IIa clinical trial since July 2016 by AstraZeneca. Preliminary data indicated that RG-125/AZD4076 can improve insulin sensitivity in Type 2 diabetes and non-alcoholic fatty liver diseases. However, the development of RG-125/ AZD4076 has been halted as the clinical programs were scuttled in June 2017. 150 MRX34, a liposome-based miR-34 mimic, has entered a Phase I clinical trial in patients with advanced HCC.
151 MRX34 appears to act as a tumor suppressor by inhibiting multiple oncogenic pathways and stimulating anti-tumor immune responses. However, due to multiple immune-related severe adverse events (SAEs) observed in study patients, the clinical Phase I study for MRX34 was halted on 20 September 2016. 152 TargomiRs, a miR-16-based miRNA mimic, is going into phase I clinical trials to treat patients with recurrent thoracic cancer. 153 The miR-16 family has been implicated as a tumor suppressor in a range of cancer types, and now TargomiRs is being tested for safety and effectiveness against malignant pleural mesothelioma (MPM) and non-small cell lung cancer (NSCLC). These miR-mimics usually reduce infarct volume and edema, and improve acute neurological outcomes and long-term functional recovery. For example, lentiviral overexpression of miR-29b or intracerebroventricular (ICV) administration of miR-29c mimic before MCAO attenuated stroke-induced infarction, edema, BBB disruption, and improved functional recovery. [159] [160] [161] Overexpression of miR-124 by mimic, viral vector, modified liposomes and constructed exosomes before or after MCAO significantly reduced infarction volume and functional impairment in mice, and enhanced neuronal survival and neurovascular remodeling. 61, [164] [165] [166] [167] Pre-and post-stroke upregulation of miR-424 with lentivirus and miR-424 mimic decreased cerebral infarction size and brain edema after MCAO, by inhibiting neuronal apoptosis, microglial activation, and oxidative stress. 59, 170 Moreover, ICV injection of miR-139-5p mimic attenuated the infarct volume and inhibited neuronal apoptosis in a rat neonatal hypoxia-ischemia model. 171 ICV injection of let-7c-5p mimic decreased infarct volume and attenuated neurological deficits by suppressing microglial and caspase-3 activation. 172 Furthermore, IV miR-122 mimic decreased neurological deficits and brain infarction volume, maintained vessel integrity and attenuated pro-inflammatory cytokines. 180 IV administration of miR-17-92 cluster-enriched exosomes in rats after MCAO significantly improved neurological function and enhanced oligodendrogenesis, neurogenesis and neurite remodeling/neuronal dendrite plasticity in the ischemic boundary zone. 163 IV administration of miR-363 mimic after MCAO reduced infarct volume, preserved forebrain microvessels and improved sensory motor performance in middle-aged female rats. 183 On the other hand, a number of miRNA inhibitors have been tested in rodent stroke models as well. Inhibition of miRNAs that improve outcomes in rodent stroke models include miR-145, 184 203 Inhibition of these miRNAs reduces infarct volumes, edema, inflammation and neuronal loss, and improves neurological outcomes. ICV administration of anti-miR-320a immediately after MCAO effectively reduced brain infarct volume and brain edema in a rat model of cerebral ischemia that correlated with upregulation of aquaporins 1 and 4 mRNA and protein. 185 We reported that ICV infusion of an miR-497 antagomir knocked down cerebral miR-497, enhanced antiapoptotic proteins in the ischemic region, decreased infarction volumes and improved neurological outcomes in mice after focal cerebral ischemia. 49 Similarly, an antagomir of miR-let-7f reduced cortical and striatal infarcts and preserved sensorimotor function in intact female rats but not in males or ovariectomized females after stroke. 50 MiR-181a inhibition Figure 4 . MicroRNA-based therapeutics for CNS injuries in experimental animal models. In the brain or spinal cord, downregulating miRNA expression by specific miRNA inhibitors, or upregulating miRNA expression by specific miRNA mimics in experimental animal models of stroke, traumatic brain injury (TBI) or spinal cord injury (SCI) revealed potential therapeutic effects against these CNS injuries. Currently, the delivery methods for the miRNA mimics or inhibitors mainly include intracerebroventricular (ICV) injection, continuous ICV infusion with osmotic minipumps, intravenous (IV) administration, intranasal administration, intrathecal administration, virus-mediated delivery, exosome-mediated delivery and stem cell-mediated delivery. In addition, a number of miRNA-based drugs have been administrated to experimental animals by combined methods to achieve the maximal delivery efficacy.
alleviated stroke-induced brain injury by increasing GRP78 protein and anti-apoptotic proteins expression, and reducing apoptosis and inflammation. 51, 186, 187 MiR-155 and miR-493 inhibitors improved blood flow, angiogenesis, and neurological function after stroke. [191] [192] [193] 196 Moreover, pretreatment with miR200c antagomir protected against post-stroke neurological deficits by increasing Reelin, a regulator of neuronal migration and synaptogenesis. 58 Pretreatment with miR-150 antagomir protected BBBassociated proteins to preserve BBB integrity during stroke. 204 Systematic administration of miR-106b-5p antagomir decreased neurological deficits and infarct volumes that correlated with inhibiting apoptosis and oxidative stress after cerebral ischemia. 200 We also showed that IV miR-15a/16-1 antagomir reduced cerebral infarct volume and brain water content, and improved neurological outcomes following stroke that correlated with upregulation of anti-apoptotic proteins and decreasing proinflammatory molecules. 60 
MiRNA-based therapeutics for TBI
Several miRNA mimics have been demonstrated to exert neuroprotection against TBI in experimental animal models. MiR-23a and miR-27a mimics injected into the brain ventricles significantly attenuated cortical lesion volume and neuronal cell loss in hippocampus of a mouse TBI model. 205, 206 Similarly, miR-21 mimic alleviated brain edema, decreased BBB damage and loss of tight-junction proteins, lessened lesion volume and improved long-term neurological function after TBI. 63, 207 Lentiviral overexpression of miR-23b decreased lesion volume, brain edema, and neurological deficits, and improved cognition. 208 IV injection of exosomes wrapped miR-124-3p mimics inhibited neuronal inflammation and promoted neurite outgrowth in mice after experimental TBI. 209 To our knowledge, two miRNA inhibitors have also been found to exhibit protective effects against TBI. Central administration of a miR-711 hairpin inhibitor reduced cortical lesion volume, neuronal cell loss in cortex and hippocampus, and alleviated long-term neurological dysfunction in a mouse TBI model. 210 Similarly, a miR-144 antagomir reduced lesion volume, alleviated brain edema and improved cognitive functions in a rat TBI model. [212] [213] [214] 216 The miR-210 mimic promoted angiogenesis and astrogliosis and improved functional recovery in a mouse SCI model. 218 MiR-27a ameliorated inflammatory damage at the blood-spinal cord barrier (BSCB) after spinal cord ischemia/reperfusion, 220 and miR-21 mimic exerted neuroprotective effects in spinal cord against ischemia/reperfusion injury. 224 Inhibition of specific dysregulated miRNAs by miRNA inhibitors can also effectively reduce the detrimental outcomes after SCI. A miR-20a inhibitor injected into the injured spinal cord promoted motor neuron survival and neurogenesis. 229 Intrathecal administration of a miR-486 inhibitor to the injured site ameliorated spinal cord damage and improved motor function. 230 Similarly, a miR-223 antagomir protected injured spinal cord and promoted functional recovery of the hindlimbs. 231 The lentiviral-antagomir-320 when administered before SCI improved hind-limb motor function and increased the number of intact motor neurons in the lumbar spinal cord after SCI. 232 Intraspinal injection of adenoassociated virus (AAV)-miR-383 infected BMSCs increased intact tissue, decreased cavity volume, and enhanced recovery of locomotor activity in rats following SCI. 233 
MiRNA-based therapeutics for SCI
Delivery methods of miRNA-based drugs to the CNS
The BBB limits the direct access of most compounds to the brain or spinal cord. Several methods have been developed for delivery of miRNA-based drugs to the CNS for the treatment of stroke, TBI and SCI (Figure 4) . ICV injection. ICV injection, which bypasses the BBB, is often used to deliver miRNA-based drugs to the brain in experimental animal models. 234 MiRNA mimics delivered via ICV injection include: miR-29c, 161 227, 228 and miR-383. 233 As an example, miR-126 mimic injected via subdural catheters seven days after SCI increased levels of miR-126, promoted angiogenesis and inhibited leukocyte extravasation into injured spinal cord. 221 IV injection. Recent methods have been developed to facilitate miRNA crossing the BBB including modifications of mimics and inhibitors, delivery via PEG lysosomes and other methods. IV injection has many advantages including ease, large administration volumes, 236 potential for reaching all injured tissues, and most importantly, it is clinically applicable with little risk. 212 An IV miR-155 inhibitor decreased miR-155, promoted brain angiogenesis, reduced tissue damage and improved functional recovery in a mouse stroke model. 191 IV administration of other inhibitors including miR-181, 187 miR-383, 199 miR-106-5p, 200 miR-15a/ 16-1 60 and miR-337-3p, 203 and IV mimics including miR-124, 61 miR-9, 178 miR-122, 180 miR-93 182 and miR-363 183 decreased damage and improved function in rodent stroke models.
Intranasal administration. Intranasal administration is also a non-invasive, and potentially clinically relevant approach for drug delivery to bypass the BBB and allow access to the CNS. 237 It can avoid fast systemic clearance and potentially decrease side-effects. 198 Peptides, proteins, vectors and even stem cells have been delivered intranasally mostly in rodents to treat CNS injuries including stroke. 237, 238 Intranasal and ICV administration of the LNA-miR-210 inhibitor 4 h post-hypoxia ischemia in neonatal rats produced similar decreases of tissue damage and improvements in neurological function later in life. 198 Virus-mediated delivery. Modified AAV and lentiviruses can deliver siRNA/shRNA into targeted genomes. 239 Similar viral overexpression of miR-29b, 159 169 and knockdown of miR-30a 52 and miR-134 57 have improved stroke outcomes. Lentivirus overexpression of miR-23b 208 and miR-27a 206 improved outcomes following rodent TBI. Lentiviral inhibition of miR-320 232 and miR-124 235 protected spinal cords against ischemia-reperfusion injury and improved hindlimb motor function. Though viral studies can provide proof-of-concept, they would have little clinical application if they have to be delivered prior to injury.
Exosome-mediated delivery. Exosomes are endogenous, cell-secreted nano-scale diameter vesicles. Exosomes appear to cross the BBB and carry cargoes such as proteins, lipids and nucleotides (mRNAs and miRNAs) to mediate brain remodeling after stroke. 167, [240] [241] [242] Several miRNAs were shown to be delivered to the brain by exosomes based on their ability to carry miRNAs. 240 IV miR-124-loaded RVG-Lamp2b-modified exosomes injected after brain ischemia promoted cortical neural progenitor cell differentiation, cortical neurogenesis, and protected against ischemic brain injury. 167 IV miR-17-92 cluster-enriched exosomes improved neurological function following a stroke and enhanced oligodendrogenesis, neurogenesis, and neurite remodeling in the ischemic penumbra. 163 Stem cell-mediated delivery. Various stem cells, including bone marrow-derived mesenchymal stem cells (MSCs), embryonic stem cells (ESCs), and induced pluripotent stem cells (iPSCs), have been used to treat experimental stroke, TBI and SCI, [243] [244] [245] [246] [247] [248] [249] [250] [251] [252] and some of these are in clinical trials. [253] [254] [255] [256] [257] [258] [259] [260] [261] However, stems cells do have limitations, mainly in terms of differentiation potential, tumorigenic activity and others. [262] [263] [264] Since miRNAs are key regulators of stem cell renewal and differentiation, miRNAs have been used for bioengineering stem cells to overcome these hurdles. [265] [266] [267] Although no reports of the miR-engineered stem cells are being tested in treatment of patients with CNS injuries yet, recent studies have demonstrated that miR-engineered stem cells (i.e. miR-705, miR-381, miR-17-92, miR-124 over-expressed bone MSCs or NSCs) versus non-engineered ones can improve functional outcomes following various experimental CNS injuries. 163, 212, [268] [269] [270] MiRNA often are contained in exosomes, and can be used as a method to shuttle miRNA from one cell to another. This may have potential to modulate stem cells in a manner that is beneficial following stroke or TBI. In a rat MCAO stroke model, exosomes enriched in miR-17-92 cluster administers by IV injection resulted in improved neurological function and enhanced oligodendrogenesis, neurogenesis and neurite remodeling in the ischemic boundary zone. 163 Authors promoted this may be mediated through miRNAmediated downregulation of PTEN, Akt, mTOR and BSK-3B activity. 163 With further study, potentially specific microRNA delivery with exosomes could be a novel approach to treat neurological disease and improve outcomes.
Time windows and dosage of miRNA-based drugs
Depending on the question being studied, miRNAbased drugs have been administered at a variety of time points from 6 days before to 10 days after MCAO. If a miRNA drug has a short half-life, multiple injections or continuous infusions may be required. Since IV injections are a clinically relevant method, most groups deliver miRNA-based drugs intravenously from 5 min to 4.5 h after MCAO, the therapeutic window for tPA in humans and during a time there is salvageable penumbra. Drugs administered one day and later after MCAO usually do not affect infarct volumes, but can sometimes improve behavioral outcomes during the recovery phases following MCAO. Viruses take time to express miRNA mimics or inhibitors and thus may injected 1 day to 14 days prior to the MCAO. The optimal time windows for administration of miRNA-based drugs for TBI and SCI must be determined empirically and likely depend on the question being studied and the model being used.
Doses of miRNA-based drugs should produce significant effects on predicted target genes, with mimics usually decreasing expression, and antagonists increasing expression of predicted targets. Half-life must be assessed to determine whether multiple injections or infusions are needed. Practically, dosing depends on delivery methods and animals used. For intraventricular injections in mice, concentrations ranged from 3 pmol/ml 188 to 100 pmol/ml, 181 with a single ICV injection of < 10 ml, followed by continuous infusion at 1 ml/ h for 72-120 h. For ICV injections in rats, concentrations range from 5 pmol/ml to 25 nmol/ml with similar volumes as mice. For IV injections of 50-100 ml in mice post MCAO, concentrations varied from 30 pmol/ g 60, 187 to 10-25 mg/g. 191, 203 For rats, similar volumes of miRNA-based drugs with concentrations of 0.6-7 mg/kg have been used. Doses of viruses carrying miRNA mimics or inhibitors are determined empirically. 162, 165, 169, 189 Mechanisms of miRNA-based therapeutics for CNS injuries Since miRNAs can regulate so much of the genome, they can have multiple mechanisms of action against CNS injuries even from a single miRNA. These include anti-excitotoxicity, anti-oxidative stress, anti-endoplasmic reticulum stress, anti-inflammation, anti-apoptosis, anti-neurodegeneration, autophagy regulation, BBB protection and edema reduction, pro-angiogenesis, and neuronal and axonal regeneration. Some of these are discussed here ( Figure 5 ).
Excitotoxicity
Several miRNA therapeutics attenuate excitotoxicity following ischemic stroke. For example, AAVmediated overexpression of miR-223 in the hippocampus lowered the levels of glutamate receptor 2 (GluR2) and NMDAR subunit 2B (NR2B), inhibited NMDA-induced calcium influx in hippocampal neurons, and protected the brain from neuronal cell death following transient global ischemia. 158 MiR181a antagomir prevented the decrease of glutamate transporter 1 and reduced astrocyte dysfunction, resulting in increased neuronal survival in the hippocampal CA1 region. 186 
Oxidative stress
Upregulation of miR-23a-3p, miR-99a and miR-424 or inhibition of miR-93 and miR-182 protected ischemic brain by decreasing oxidative stress. 56, 59, 173, 195, 197, [271] [272] [273] For example, miR-23a-3p mimic reduced production of nitric oxide (NO) and 3-nitrotyrosine (3-NT), and increased expression of manganese SOD (MnSOD) to decrease oxidative stress in a mouse MCAO model. 56 MiR-93 antagomir decreased infarction volume and improved function, 197 which correlated with increased expression level of erythroid 2-related factor (Nrf2) and its downstream gene hemeoxygenase-1 (HO-1) . 274, 275 In addition, miR-486 inhibition induced the expression of NeuroD6, which ameliorated SCI-induced ROS via upregulation of thioredoxin-like 1 (TXNL1) and glutathione peroxidase 3 (GPX3). 230 
Inflammation
Many miRNA-based drugs are anti-inflammatory. Specifically, most of the anti-inflammatory mechanisms involve the suppression of astrocytes activation, cytokines secretion and leukocyte extravasation. For example, overexpression of miR-424 and miR-let-7c-5p reduces infarct volume and improves neurological function, partially by inhibition of astrocyte activation after stroke. 170, 172 Overexpression of miR-22 and miR-122 or inhibition of miR-15a/16-1 reduces inflammatory molecules TNF-a, IL-6, MCP-1, COX-2, iNOS, and VCAM-1 in ischemic brain. 60, 177, 180 Exosome-mediated delivery of miR-124-3p promotes M2 microglia polarization and inhibits tissue inflammation following TBI. 209 MiR-27a, miR-199b, miR-124, miR-497 or miR-133b mimics inhibit SCI-induced inflammatory responses by reducing astrocyte/macrophage activation, and inhibiting NF-kB/IL-1b or IKKb-NF-kB pathways. 215, 220, 222, 226 Apoptosis Some miRNA-based drugs decrease apoptosis by decreasing pro-apoptotic proteins (e.g. Bax) and/or increasing anti-apoptotic proteins (e.g. Bcl-2, Bcl-w, Bcl-xl). [276] [277] [278] [279] MiR-497, miR-181a, miR-24, miR-15a/ 16-1 and miR-106b-5p antagomirs or miR-124 and miR-210 mimics enhance Bcl-2/-w/-xl protein levels in ischemic brain, attenuate infarction, and improve functional outcomes after stroke. 49, 60, 61, 168, 186, 194, 200 A miR-124 inhibitor reduced infarction in a mouse MCAO model by inhibiting members of the apoptosis-stimulating proteins of p53 family (iASPP). 164 MiR-23a, miR-27a, miR-21 and miR-23b decrease several pro-apoptotic proteins (e.g. Puma, Noxa, Bax, cleaved-caspase-3) in TBI. 63, 205, 208 Inhibiting miR-29b or activating miR-20a, miR-21 and miR-494 mitigates apoptosis by inhibiting phosphatase and tensin homolog (PTEN) expression and activating AKT/ mTOR signaling pathway in SCI. 228 
BBB/BSCB protection
Damage to the BBB following stroke and TBI, or the BSCB following SCI promotes entry of cytokines, chemokines, other inflammatory molecules and leukocytes that can promote tissue injury and edema. [280] [281] [282] [283] [284] This entire cascade can be mitigated by some miRNAs. Downregulating miR-150 stabilizes TJ protein ZO-1, 191 and increases claudin-5 and angiopoietin receptor Tie-2 204 to improve BBB function after stroke. AntimiR-320 or anti-mir-130 treatment upregulates the expression of aquaporins following stroke (AQP) 4, which have been implicated in cerebral edema clearance. 185, 285 MiR-320a mimic improved spinal cord ischemia/reperfusion-induced lower limb motor function, alleviated BBB disruption and decreased spinal water content by suppressing AQP1 expression. 223 
Angiogenesis
Angiogenesis, which may contribute to recovery following stroke, TBI and SCI, [286] [287] [288] is modulated by several miRNAs. MiR-107 mimic reduced ischemic brain infarction and increased the number of capillaries in the penumbra by enhancing endothelial VEGF165/ 164 levels. 174 MiR-21 mimic improvements in neurological outcome following TBI correlated in part with upregulation of VEGF, Angiopoietin-1 (Ang-1) and Tie-2 (receptor of Ang-1). 63 MiR-210 promoted angiogenesis in injured spinal cord via inhibition of proteintyrosine phosphate 1B and ephrin-A3 in rats. 218 The mir-223 antagomir also promoted angiogenesis after SCI. 231 
Neurogenesis
Neurogenesis, which occurs in many areas of brain including the subventricular zone (SVZ), the subgranular layer (SGL) of the dentate gyrus (DG) in the hippocampus, 289, 290 cortex, and spinal cord, is modulated by stroke, TBI and SCI in part via miRNA. [291] [292] [293] [294] Overexpression of the miR-17-92 cluster in the SVZ significantly increased the proliferation of NSCs and promoted neurogenesis after stroke, 162 by inhibiting its target gene PTEN, and consequently increasing the phosphorylation of protein kinase B (Akt), mechanistic target of rapamycin (mTOR), and glycogen synthase kinase 3b (GSK-3b). 163 A miR-20a inhibitor improved motor neuron survival, increased neurogenesis and improved function in mice following SCI by rescuing expression of the miR-20a target gene neurogenin 1 (Ngn1). 229 
MiRNAs as therapeutic targets of pharmacological agents in CNS injuries
In addition to miRNA mimics and inhibitors, miRNAbased therapeutics for CNS injuries may also include the pharmacological agents that exert neuroprotection via the regulation of functional miRNAs. As shown in Table 1 , several pharmacological agents that protect against stroke, TBI and SCI regulate specific miRNA that may partially mediate these effects. [295] [296] [297] [298] [299] [300] [301] [302] [303] [304] [305] [306] [307] [308] [309] VELCADE upregulates miR-146a to inactivate the ischemia and tissue plasminogen activator (tPA) potentiated toll-like receptor (TLR) signaling pathway and thus helps protects against acute ischemic stroke. 295 Arctigenin can upregulate the levels of miR-16 and miR-199a to reduce IKKa and IKKb expression and inhibit NF-kB signaling pathway and promote cholinergic signaling; 302 hydrogen gas 303 regulates oxidative stress via upregulating miR-21. Several agents that are neuroprotective in SCI also regulate several miRNAs (Table 1) , including ferulic acid which helped improve functional recovery in SCI rats by inhibiting miR-590 and increasing VEGF. 304 The therapeutic effects of several pharmacological agents, including Acetylbritannilactone (ABL), 296 Trimetazidine(TMZ), 297 Nicorandil, 300 arctigenin, 302 hydrogen gas (H 2 ), 303 hydrogen sulfide (H 2 S), 305, 306 ferulic acid 304 are depended on the modulation of specific miRNAs, since blocking the modulation of these miRNAs can completely abolish the protective effects of these agents against CNS injuries. For example, H 2 S pretreatment reduced spinal cord infarct zone and improved hindlimb motor function by downregulating miR-30c expression in a rat ischemia/reperfusion (I/R) model. MiR-30c mimic pretreatment abrogated the spinal cord protective effect of H 2 S. 305 Challenges, perspectives and future goals
One general challenge in miRNA-based therapeutics is to avoid rapid degradation by the abundant RNases in the circulation or in the endocytic compartment of cells. Although chemical modifications have helped solve this problem, the half-life of some constructs can be very short which may require repeated injections or infusions.
A major problem in the miRNA therapeutics field is potential off-target effects. Some of these occur because commercially available miRNA mimics can produce unexpected off-target effects induced by the ''passenger-strand'' of the mimics. 100 Another explanation for ''off-target'' effects is that though a given miRNA may regulate one or several target genes to improve functional outcomes following stroke, TBI and SCI, the miRNA may act on other target genes to produce unwanted side effects or even activate pathways that counteract the protective effects. Ways of increasing specificity of miRNA effects to selected target genes and blocking off-target effects are needed. Such differential effects on different target genes might explain studies where a miR-20a inhibitor improved neural cell survival following SCI 229 in one study, whereas miR-20a mimics improved neuronal survival via an anti-apoptotic pathway 219 in another study. The time course of miRNA effects on their targets must be carefully considered. For example, early administration of miR-124 mimic to ischemic brain significantly increased neuronal survival, whereas later administration did not. 166 MiRNA delivery for CNS injuries, like all pharmacological agents, is complicated by the need to circumvent or penetrate the BBB or BSCB. This explains why nearly 2/3 of published studies have used ICV administration or intrathecal injection to bypass the BBB or BSCB. Though such studies demonstrate proof-of-principle, they usually would not translate to humans. Viral-mediated knockdown or overexpression of miRNAs usually requires time, so that this method would not be useful in acute CNS injuries, but could be considered during recovery if any immune reactions are carefully assessed and controlled. Nasal administration appears to allow some compounds to gain access to brain, though most of these studies have been performed in rodents, and it is not clear that such methods can be translated to humans with a different anatomy. Nasal administration is also complicated potentially by inconsistent delivery in patients with upper respiratory infections or sinus infections, but has the theoretical advantage of avoiding systemic side effects. IV injection is the accepted method, but requires chemical modifications of miRNA mimics and antagomiRs to obtain cell and BBB penetration. Systemic off-target effects can become problematic. Despite these challenges, tissuespecific and cellular receptors targeted AAV has provided an exciting way to deliver miRNA to the places of interest, and is currently in use in a number of preclinical models and clinical trials for gene therapy in cancer. 95 It is possible exosomes, with or without stem cells, or engineered nanoparticles-miRNA-based drugs may improve the ability to cross the BBB and to avoid delivery to unwanted sites. In stroke therapies, numerous neuroprotective agents have been proven effective in various preclinical animal studies. 310 Unfortunately, none of them yield translational efficacy in clinical trials. Most large vessel ischemic stroke patients have permanent occlusion and could not restore the blood flow to allow effective concentration of neuroprotectants in the affected brain areas might account for this mismatch. 311, 312 Currently, none of miR-based drugs have been advanced to the development of clinical stroke therapies. If following the traditional way for previously tested neuroprotectants to evaluate miRbased drugs for stroke therapy, there may be a long way to go for the success in clinical trials. Fortunately, by using salvageable penumbral tissue criteria, recent DAWN trials revealed that thrombectomy has brought about significant benefits for acute ischemic stroke patients up to 24 h since symptom onset. [313] [314] [315] In this context, combination therapy of selected miR-based drugs and recanalization via endovascular thrombectomy might provide new insight for the treatment of ischemic stroke in the future.
Many previous studies have not considered that miRNAs are differentially expressed in neurons, astrocytes, oligodendrocytes, and microglia in the CNS, 316 and there is a specific complement of endothelial cell miRNAs that are likely to be important in stroke, TBI and SCI. 317 Understanding the functions of miRNAs in specific cell types under normal and pathological conditions could improve specificity and efficacy of miRNA strategies. More attention should also be paid to elucidate the downstream therapeutic targets of specific miRNA in specific cell types following CNS injuries, and to identify target genes that produce unwanted side effects.
Although numerous studies demonstrated the possible signaling pathways and miRNA target genes, the functional significance of many of the target genes in mediating therapeutic effects of miRNA-base drugs were not further verified by means of overexpression, knockdown, or functional inhibition. Additional mechanistic investigations of miRNA target genes are needed to elucidate the underlying mechanisms of miRNA-based therapeutics towards CNS injuries.
Male animals have been mostly utilized in miRNAbased therapeutic applications in vivo. However, brain miRNA responses differ following focal cerebral ischemia between male and female mice, 318, 319 and sex can affect stroke outcomes. [320] [321] [322] Thus, more effort should be devoted to include female animals in the experimental design. Indeed, there have been significant differences regarding miRNA-based therapeutics between male and female animals. For example, miR-363-3p mimics reduced the caspase-3 activity and brain infarct volumes in middle-aged female mice, but had no effects on stroke outcomes or caspase activities in young males. 183 Despite the challenges, miRNA-based therapeutics have become promising strategies for CNS injuries. Much remains to be done to understand how miRNA exert their effects via hundreds of targets, developing approaches to identify candidate miRNAs, designing chemical formulations and delivery methods to target brain and cross the BBB, and methods to decrease off target effects. Successful clinical trials and clinically effective miRNA drugs will certainly enhance the future of this nascent field.
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